KIT and maculopapular cutaneous mastocytosis: The European Competence Network on Mastocytosis and the American Initiative in Mast Cell Diseases (ECNM-AIM) consortium criteria (hereafter designated “consortium MCAS criteria”) reaffirm this definition and further expand on the relation of MCAS to the broader MCA disorders (MCADs), including monoclonal (e.g. clonal mast cell disease with activating mutations in c-KIT), secondary (e.g. severe IgE-mediated hypersensitivities), and idiopathic MCAS 7.